$26.20
0.42% yesterday
Nasdaq, Jul 11, 10:00 pm CET
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

AnaptysBio, Inc. Stock price

$26.20
+2.60 11.02% 1M
+11.58 79.21% 6M
+12.96 97.89% YTD
-4.12 13.59% 1Y
+6.87 35.54% 3Y
+6.04 29.96% 5Y
+9.20 54.12% 10Y
+9.20 54.12% 20Y
Nasdaq, Closing price Fri, Jul 11 2025
+0.11 0.42%
ISIN
US0327241065
Symbol
ANAB
Sector
Industry

Key metrics

Basic
Market capitalization
$769.8m
Enterprise Value
$429.8m
Net debt
positive
Cash
$339.9m
Shares outstanding
30.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
6.9 | 11.5
EV/Sales
3.8 | 6.4
EV/FCF
negative
P/B
22.6
Financial Health
Equity Ratio
14.7%
Return on Equity
-204.9%
ROCE
-26.5%
ROIC
-138.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$111.9m | $67.0m
EBITDA
$-99.7m | $-106.2m
EBIT
$-100.3m | $-156.5m
Net Income
$-140.6m | $-164.4m
Free Cash Flow
$-109.2m
Growth (TTM | estimate)
Revenue
387.2% | -26.6%
EBITDA
38.3% | 7.2%
EBIT
38.2% | -36.1%
Net Income
13.9% | -13.2%
Free Cash Flow
18.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-89.1% | -158.5%
EBIT
-89.6%
Net
-125.7% | -245.4%
Free Cash Flow
-97.6%
More
EPS
$-4.6
FCF per Share
$-3.6
Short interest
56.2%
Employees
136
Rev per Employee
$670.0k
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a AnaptysBio, Inc. forecast:

15x Buy
83%
3x Hold
17%

Analyst Opinions

18 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
83%
Hold
17%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
112 112
387% 387%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 44 44
2% 2%
39%
- Research and Development Expense 168 168
25% 25%
150%
-100 -100
38% 38%
-89%
- Depreciation and Amortization 0.59 0.59
9% 9%
1%
EBIT (Operating Income) EBIT -100 -100
38% 38%
-90%
Net Profit -141 -141
14% 14%
-126%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Positive
Seeking Alpha
about one month ago
Rosnilimab's strong Phase IIb RA data shows sustained efficacy and safety, positioning it as a potential blockbuster in a massive RA market. Despite JNJ's class setback, AnaptysBio offers significant upside, with fair value estimates nearly double its current market cap if RA approval is secured. Key risks include future cash needs, execution challenges, and tough competition, so I maintain a 2...
Positive
Seeking Alpha
about one month ago
AnaptysBio, Inc.'s rosnilimab showed strong phase 2b results in moderate-to-severe RA, achieving key efficacy and safety endpoints, supporting its potential in a $20B U.S. market. Rosnilimab is also being evaluated in a phase 2 trial for moderate-to-severe ulcerative colitis, targeting a $15.8B global market, with data expected in Q4 2025. ANAB has sufficient cash for at least 12 months but may...
Neutral
GlobeNewsWire
about one month ago
SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational rosnilimab, a depleter and agonist targeting PD-1+ T cells, demonstrated a best-in-disease profile in patients with moderate-to-severe rheumatoid arthritis (RA). In the robust, global 4...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 136
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today